As a National Clinic Trials Network Lead Academic Participating Site, we hope to accomplish the following: 1. To provide scientific leadership and intellectual input in the creation of thoughtful, feasible trials to improve the health of cancer patients. We will accomplish this aim through the ongoing participation in clinical trials that spn the spectrum of disease-specific and radiation and surgical oncology; by applying the UNC culture of multidisciplinary care to make NCTN trials stronger and more modern; by leveraging the commitment of junior faculty, who will be the leaders of tomorrow; and by applying health services research in the development of clinical trials, including factors important to clinical outcomes, such as cost effectiveness, delivery of care, and policy. 2. To continue to be strong supporters of Network trials, through our rapidly growing clinical enterprise and robust accrual. We will support this aim by building on our historically strong accrual to CALGB, GOG, and ACOSOG trials and our well-funded and organized infrastructure, and through active participation across the NCTN. 3. To provide opportunities for excellent translational science embedded in NCTN clinical trials. UNC has a long commitment to translational science and has served as reference lab across multiple trials, with substantial (more than $3 million) investment in Next Generation sequencing and genomics; we are well suited to serve as a translational research collaborator for clinical trials in the future.
The UNC Lineberger Lead Academic Participating Site brings together an accomplished group of academic clinical oncologists and faculty from related disciplines, organized into multidisciplinary disease-site groups, to undertake cutting edge clinical research across the spectrum of cancers. The UNC LAPS will commit the staff and professional resources to manage and evaluate these research activities, accrue patients, and share knowledge with the wider research community. This effort will serve to enhance the understanding of cancer progression and treatment, lead to new studies based on information learned, and improve outcomes for patients.
|Gajra, Ajeet; McCall, Linda; Muss, Hyman B et al. (2018) The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). J Geriatr Oncol 9:221-227|
|Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304|
|Tallarico, Michael; Foster, Jared C; Seisler, Drew et al. (2018) Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). J Geriatr Oncol 9:321-328|
|Gounder, Mrinal M; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379:2417-2428|
|Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506|
|Morrison, Vicki A; McCall, Linda; Muss, Hyman B et al. (2018) The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). J Geriatr Oncol 9:228-234|
|Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121|
|Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334|
|Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol 20:546-556|
|Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332|
Showing the most recent 10 out of 86 publications